Skip to main content
SpringerLink
Log in

Nitric Oxide—Induced Immunosensitization to Apoptosis by Fas-L and TRAIL

  • Chapter
Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 1072 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 229.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Baritaki S, Huerta-Yepez S, Sakai T, et al. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther 2007, 6:1387–1399.

    Article  CAS  PubMed  Google Scholar 

  2. Blaise GA, Gauvin D, Gangal M, et al. Nitric oxide, cell signaling and cell death. Toxicology 2005, 208:177–192.

    Article  CAS  PubMed  Google Scholar 

  3. Bogdan C. Nitric oxide and the regulation of gene expression. Trends Cell Biol 2001, 11:66–75.

    Article  CAS  PubMed  Google Scholar 

  4. Benz S, Obermaier R, Wiessner R, et al. Effect of nitric oxide in ischemia/reperfusion of the pancreas. J Surg Res 2002, 106:46–53.

    Article  CAS  PubMed  Google Scholar 

  5. Tuteja N, Chandra M, Tuteja R, et al. Nitric oxide as a unique bioactive signaling messenger in physiology and pathophysiology. J Biomed Biotechnol 2004, 2004:227–237.

    Article  PubMed  Google Scholar 

  6. Hess DT, Matsumoto A, Kim SO, et al. Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol 2005, 6:150–166.

    Article  CAS  PubMed  Google Scholar 

  7. Myers PR, Minor RL Jr, Guerra R Jr, et al. Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitroso-cysteine than nitric oxide. Nature 1990, 345: 161–163.

    Article  CAS  PubMed  Google Scholar 

  8. Bonavida B, Khineche S, Huerta-Yepez S, et al. Therapeutic potential of nitric oxide in cancer. Drug Resist Updat 2006, 9:157–173.

    Article  CAS  PubMed  Google Scholar 

  9. Fukuo K, Hata S, Suhara T, et al. Nitric oxide induces upregulation of Fas and apoptosis in vascular smooth muscle. Hypertension 1996, 27:823–826.

    CAS  PubMed  Google Scholar 

  10. Garban HJ, Bonavida B. Nitric oxide disrupts H2O2-dependent activation of nuclear factor kappa B. Role in sensitization of human tumor cells to tumor necrosis factor-alpha -induced cytotoxicity. J Biol Chem 2001, 276:8918–8923.

    Article  CAS  PubMed  Google Scholar 

  11. Garban HJ, Bonavida B. Nitric oxide sensitizes ovarian tumor cells to Fas-induced apoptosis. Gynecol Oncol 1999, 73:257–264.

    Article  CAS  PubMed  Google Scholar 

  12. Park IC, Woo SH, Park MJ, et al. Ionizing radiation and nitric oxide donor sensitize Fas-induced apoptosis via up-regulation of Fas in human cervical cancer cells. Oncol Rep 2003, 10:629–633.

    CAS  PubMed  Google Scholar 

  13. Garban HJ, Bonavida B. Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of the Fas promoter: a pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells. J Immunol 2001, 167:75–81.

    CAS  PubMed  Google Scholar 

  14. Coull JJ, Romerio F, Sun JM, et al. The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol 2000, 74:6790–6799.

    Article  CAS  PubMed  Google Scholar 

  15. Vega MI, Jazirehi AR, Huerta-Yepez S, et al. Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresist-ance, respectively. J Immunol 2005, 175:2174–2183.

    CAS  PubMed  Google Scholar 

  16. Hongo F, Garban H, Huerta-Yepez S, et al. Inhibition of the transcription factor Yin Yang 1 activity by S-nitrosation. Biochem Biophys Res Commun 2005, 336:692–701.

    Article  CAS  PubMed  Google Scholar 

  17. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999, 11:255–260.

    Article  CAS  PubMed  Google Scholar 

  18. Ashkenazi A, Pai RC, Fong S, et al. Safety and anti-tumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999, 104:155–162.

    Article  CAS  PubMed  Google Scholar 

  19. de Jong S, Timmer T, Heijenbrok FJ, et al. Death receptor ligands, in particular TRAIL, to overcome drug resistance. Cancer Metastasis Rev 2001, 20: 51–56.

    Article  PubMed  Google Scholar 

  20. Wajant H, Pfizenmaier K, Scheurich P. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis 2002, 7:449–459.

    Article  CAS  PubMed  Google Scholar 

  21. Chawla-Sarkar M, Bauer JA, Lupica JA, et al. Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL. J Biol Chem 2003, 278:39461–39469.

    Article  CAS  PubMed  Google Scholar 

  22. Zisman A, Ng CP, Pantuck AJ, et al. Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis. J Immunother (1997) 2001, 24:459–471.

    Article  CAS  PubMed  Google Scholar 

  23. Ng CP, Zisman A, Bonavida B. Synergy is achieved by complementation with Apo2L/TRAIL and actino-mycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Prostate 2002, 53:286–299.

    Article  CAS  PubMed  Google Scholar 

  24. Bouralexis S, Findlay DM, Atkins GJ, et al A. Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/ TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. Br J Cancer 2003, 89:206–214.

    Article  CAS  PubMed  Google Scholar 

  25. Tillman DM, Izeradjene K, Szucs KS, et al. Rottlerin sensitizes colon carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via uncoupling of the mitochondria independent of protein kinase C. Cancer Res 2003, 63:5118–5125.

    CAS  Google Scholar 

  26. Munshi A, McDonnell TJ, Meyn RE. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells. Cancer Chemother Pharmacol 2002, 50:46–52.

    Article  CAS  PubMed  Google Scholar 

  27. Park SY, Billiar TR, Seol DW. IFN-gamma inhibition of TRAIL-induced IAP-2 upregulation, a possible mechanism of IFN-gamma-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun 2002, 291:233–236.

    Article  CAS  PubMed  Google Scholar 

  28. Nyormoi O, Mills L, Bar-Eli M. An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells. Cell Death Differ 2003, 10:558–569.

    Article  CAS  PubMed  Google Scholar 

  29. Huerta-Yepez S, Vega M, Jazirehi A, et al. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene 2004, 23:4993–5003.

    Article  CAS  PubMed  Google Scholar 

  30. Lee YJ, Lee KH, Kim HR, et al. Sodium nitroprus-side enhances TRAIL-induced apoptosis via a mitochondria-dependent pathway in human colorectal carcinoma CX-1 cells. Oncogene 2001, 20:1476–1485.

    Article  CAS  PubMed  Google Scholar 

  31. Secchiero P, Gonelli A, Celeghini C, et al. Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factor-related apoptosis-inducing ligand-mediated cytotoxicity on hematologic malignancies. Blood 2001, 98:2220– 2228.

    Article  CAS  PubMed  Google Scholar 

  32. Shigeno M, Nakao K, Ichikawa T, et al. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation. Oncogene 2003, 22:1653–1662.

    Article  CAS  PubMed  Google Scholar 

  33. LaVallee TM, Zhan XH, Johnson MS, et al. 2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res 2003, 63:468–475.

    CAS  PubMed  Google Scholar 

  34. Johnston JB, Kabore AF, Strutinsky J, et al. Role of the TRAIL/APO2-L death receptors in chlo-rambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia. Oncogene 2003, 22:8356–8369.

    Article  CAS  PubMed  Google Scholar 

  35. Yoshida T, Maeda A, Tani N, et al. Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene. FEBS Lett 2001, 507:381–385.

    Article  CAS  PubMed  Google Scholar 

  36. Lu D, Mahmood A, Zhang R, et al. Upregulation of neurogenesis and reduction in functional deficits following administration of DEtA/NONOate, a nitric oxide donor, after traumatic brain injury in rats. J Neurosurg 2003, 99:351–361.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported in part by the Department of Defense (DOD)/US Army DAMD 17-02-1-0023 and the Fogarty International Center Fellowship (D43 TW00013–14) (S.H.-Y., M.V., and U.C. MEXUS-Conacyt (S.H.-Y.), Research Supplement for Minorities from the PHS/NIH/NCI/CMBB ROI CA79976 to H.G., and a philanthropic contribution from the Ann C. Rosenfield Fund under the direction of David Leveton. We also acknowledge the assistance of Tania Golkar and Alina Katsman in the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Department of Microbiology, Immunology, and Molecular Genetics, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, CA

    Benjamin Bonavida, Sara Huerta-Yepez, Mario I. Vega & Stravoula Baritaki

  2. Department of Clinical Virology, Faculty of Medicine, University of Crete, Heraklion, Greece

    Demetrios A. Spandidos

Authors
  1. Benjamin Bonavida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sara Huerta-Yepez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mario I. Vega
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Demetrios A. Spandidos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stravoula Baritaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of California at Los Angeles, Los Angeles, CA, USA

    Benjamin Bonavida PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Bonavida, B., Huerta-Yepez, S., Vega, M.I., Spandidos, D.A., Baritaki, S. (2008). Nitric Oxide—Induced Immunosensitization to Apoptosis by Fas-L and TRAIL. In: Bonavida, B. (eds) Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-474-2_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-474-2_13

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-29-9

  • Online ISBN: 978-1-59745-474-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation